Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study
Titel:
Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study
Auteur:
Yamamoto, N. Seto, T. Nishio, M. Goto, K. Yamamoto, N. Okamoto, I. Yamanaka, T. Tanaka, M. Takahashi, K. Fukuoka, M.